Identification of SNPs associated with methotrexate treatment outcomes in patients with early rheumatoid arthritis

Methotrexate is one of the cornerstones of rheumatoid arthritis (RA) therapy. Genetic factors or single nucleotide polymorphisms (SNPs) are responsible for 15%–30% of the variation in drug response. Identification of clinically effective SNP biomarkers for predicting methotrexate (MTX) sensitivity h...

Descripción completa

Detalles Bibliográficos
Autores principales: Kolan, Shrikant S., Li, Gaoyang, Grimolizzi, Franco, Sexton, Joe, Goll, Guro, Kvien, Tore K., Sundlisæter, Nina Paulshus, Zucknick, Manuela, Lillegraven, Siri, Haavardsholm, Espen A., Skålhegg, Bjørn Steen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9714492/
https://www.ncbi.nlm.nih.gov/pubmed/36467057
http://dx.doi.org/10.3389/fphar.2022.1075603

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9714492/
https://www.ncbi.nlm.nih.gov/pubmed/36467057
http://dx.doi.org/10.3389/fphar.2022.1075603

Ejemplares similares